Compare AbbVie Inc (ABBV) vs Hershey Co (HSY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Hershey Co — how do they compare? AbbVie Inc trades at $249.21 (market cap $441.94B), while Hershey Co trades at $182.1 (market cap $36.56B). The key difference: AbbVie Inc is far larger — about 12.1× Hershey Co's market cap, and Hershey Co pays the higher dividend (3.19%). Which is the better fit depends on your goals.
| ABBV | HSY | |
|---|---|---|
Market Cap | $441.94B | $36.56B |
Sector | Health | Consumer Staples |
52-Week High | $263.58 | $236.28 |
52-Week Low | $197.38 | $162.31 |
Enterprise Value | $506.19B | $41.70B |
Dividend Yield | 2.77% | 3.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $249.9, up 0.8% on the day, with strong analyst support (29 Buy, 1 Sell) and a $278.69 consensus price target. Recent quarterly earnings have consistently beaten estimates, driven by robust immunology drug sales. The stock shows a bullish technical trend, supported by moving averages, and the company maintains solid cash flow and dividend payments.
Outlook is positive with revenue growth and pipeline advancements, though high P/E and debt levels pose risks. The stock offers a compelling buy case for growth and income investors, balanced by execution and patent expiry challenges ahead.
Hershey (HSY) trades at $182.75, up 0.22% with a bullish technical signal and strong fundamental momentum. The stock shows consistent earnings beats with Q2 2026 EPS of $1.90 exceeding expectations by 33%, while revenue growth trends upward to $11.69 billion in 2025. Analyst consensus targets $196.78 with 69% hold ratings, reflecting cautious optimism amid margin recovery from favorable cocoa contracts and dividend growth.
The outlook remains positive with earnings rebound and pricing power, though risks include volume declines and competitive pressures. Current valuation at 24.86 P/E appears reasonable given 32.81% ROE and improving cash flow trends. Institutional sentiment is mixed with recent insider sales offset by upward guidance revisions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Hershey Co
Hershey is a leading confectionery manufacturer in the U.S. (around a $25 billion market), controlling around 46% of the domestic chocolate space (per IRI). Beyond its namesake label, the firm's mix has expanded over the last 85 years and now consists of 100 brands, including Reese's, Kit Kat, Kisses, and Ice Breakers. Hershey's products are sold in about 80 countries, albeit with just a high-single-digit percentage of sales coming from markets outside the U.S., including Brazil, India, and Mexico. The firm has sought inorganic opportunities to extend its reach beyond its core confection business, adding Amplify Snack Brands and its Skinny Pop ready-to-eat popcorn to its mix and Pirate Brands (including the Pirate's Booty, Smart Puffs, and Original Tings brands) over the past few years.
Read more on HSY →
